Design, Synthesis, Antibacterial Evaluation and Docking Study of Novel 2‐Hydroxy‐3‐(nitroimidazolyl)‐propyl‐derived Quinolone. (16th August 2014)

• Record Type: Journal Article
• Authors: Li, Qing; Xing, Junhao; Cheng, Haibo; Wang, Hui; Wang, Jing; Wang, Shuai; Zhou, Jinpei; Zhang, Huibin
• Is Part Of: Chemical biology & drug design. Volume 85:Number 1(2015:Jan.)
• Page Start: 79
• Page End: 90
• Publication Date: 2014-08-16
• Subjects: Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.12395
• Languages: English
• ISSNs: 1747-0277

Abstract

<abstract abstract-type="main" id="cbdd12395-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>A novel series of 2‐hydroxy‐3‐(nitroimidazolyl)‐propyl‐derived quinolones <bold>6a</bold>–<bold>o</bold> were synthesized and evaluated for their <italic>in vitro</italic> antibacterial activity. Most of the target compounds exhibited potent activity against Gram‐positive strains. Among them, moxifloxacin analog <bold>6n</bold> displayed the most potent activity against Gram‐positive strains including <italic>S. epidermidis</italic> (MIC = 0.06 <italic>μ</italic>g/mL), MSSE (MIC = 0.125 <italic>μ</italic>g/mL), MRSE (MIC = 0.03 <italic>μ</italic>g/mL), <italic>S. aureus</italic> (MIC = 0.125 <italic>μ</italic>g/mL), MSSA (MIC = 0.125 <italic>μ</italic>g/mL), (MIC = 2 <italic>μ</italic>g/mL). Its activity against MRSA was eightfold more potent than reference drug gatifloxacin. Finally, docking study of the target compound <bold>6n</bold> revealed that the binding model of quinolone nucleus was similar to that of gatifloxacin and the 2‐hydroxy‐3‐(nitroimidazolyl)‐propyl group formed two additional hydrogen bonds.</p> </abstract>